A personalised taper-to-target strategy with adalimumab in Crohn's disease. Dreesen E, Verstockt B. Lancet Gastroenterol Hepatol 2023 Jan 31:S2468-1253(23)00009.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Dreesen E, Verstockt B. A personalised taper-to-target strategy with adalimumab in Crohn's disease. Lancet Gastroenterol Hepatol 2023 Jan 31:S2468-1253(23)00009.
PMID: 36736340